Furmonertinib demonstrated efficacy in a case of advanced pancreatic cancer with a 19-exon deletion mutation and wild-type KRAS: a case report and literature review.

In China, advanced pancreatic cancer (PC) is known as the "king of cancers" due to its high treatment difficulty and extremely short survival period. Currently, advanced pancreatic cancer is mainly treated with chemotherapy. The 5-year survival rate is approximately 14.4% for patients with locally advanced pancreatic cancer and only 3% for those with distant metastasis. There are currently no effective targeted drugs for pancreatic cancer. This article reports a case of a patient with advanced pancreatic cancer harboring an EGFR exon 19 deletion. The patient received furmonertinib as third-line therapy, achieving a progression-free survival (PFS) of 6.3 months. Subsequently, drug resistance occurred; increasing the dose of furmonertinib showed no efficacy. Later, a combination of furmonertinib and anlotinib was administered, which successfully overcame the resistance. After follow-up, the patient passed away at home on 22 January 2026. The overall survival time was approximately 38 months. This case suggests that furmonertinib may be effective in patients with pancreatic cancer patients harboring an EGFR exon 19 deletion and that the combination of anlotinib and furmonertinib may overcome resistance to furmonertinib. This is only a case report, and these findings warrant further investigation.